Japan’s second-largest pharmaceutical company Daiichi Sankyo will buy up to 51 per cent stake in Ranbaxy Laboratories at Rs 737 a share.The transaction is expected to be completed by the end of March 2009.
If you wish to buy Ranbaxy Now. Read this BusinessLine article before placing Buy order.
Low acceptance ratio, capital gains tax and likely dilution of equity veto buying
0 comments:
Post a Comment
All comments are moderated. Please post no spam